Johnson & Johnson Sees $1.69 Million in Unusual Call Activity Across Three Contracts

By TrendSpider Editor

Johnson & Johnson is attracting notable bullish options interest today, with three unusual call contracts totaling $1,687,150 in premium hitting the tape as shares trade at $256.18, down 0.55% on the session. All three contracts are calls, suggesting options traders are positioning for upside in JNJ

Johnson & Johnson Sees $1.69 Million in Unusual Call Activity Across Three Contracts

Johnson & Johnson is attracting notable bullish options interest today, with three unusual call contracts totaling $1,687,150 in premium hitting the tape as shares trade at $256.18, down 0.55% on the session. All three contracts are calls, suggesting options traders are positioning for upside in JNJ over the coming weeks and months. With the stock sitting closer to its 52-week high of $274.89 than its 52-week low of $166.64, the options flow arrives at a technically constructive moment in the chart.

Key Drivers of the JNJ Stock Move

• Main Catalyst: Three unusual call contracts were flagged today across strikes of $250, $260, and $265, with total premium of $1,687,150 and expirations ranging from August 21, 2026 through October 16, 2026. The largest single-premium contract was the $250 call expiring October 16, 2026, carrying $772,500 in premium.
• Bull Case: All three contracts are calls, and the $250 strike is already in the money with JNJ trading at $256.18. The $265 call expiring August 21, 2026, saw the highest volume of the three at 1,690 contracts, signaling a near-term directional bet that the stock could push above $265 within the next two weeks.
• Bear Case: The $260 and $265 strikes are currently out of the money, meaning JNJ would need to rally meaningfully from current levels to deliver value on those contracts. The stock is already posting a modest decline of 0.55% today, and a broader pullback from current levels near the top of its 52-week range could leave these positions underwater quickly given the short duration on the August expiration.

The forward setup for JNJ looks constructive based on the options positioning, with traders targeting a move into the $260 to $265 range before October expiration. The concentration of activity in calls with no put contracts among the unusual flow reinforces a one-sided bullish lean. JNJ has been navigating ongoing litigation and pipeline developments, and any positive catalysts on those fronts in the weeks ahead could act as a near-term trigger for the options bets made today. The October 16, 2026 expiration on two of the three contracts gives traders roughly ten weeks for the thesis to develop, while the August 21 contract demands a sharper and faster move higher.

JNJ Unusual Options Activity

• Contract 1: Call | Strike: $250 | Expiry: October 16, 2026 | Volume: 500 | Open Interest: 51% | Status: In the Money
• Contract 2: Call | Strike: $260 | Expiry: October 16, 2026 | Volume: 500 | Open Interest: 49% | Status: Out of the Money
• Contract 3: Call | Strike: $265 | Expiry: August 21, 2026 | Volume: 1,690 | Open Interest: 54% | Status: Out of the Money

All three contracts were flagged as unusual, with a combined total premium of $1,687,150 and zero put contracts in the flow. The dominant volume came from the $265 call expiring in two weeks, accounting for 1,690 contracts and $397,150 in premium. The open interest percentages across all three contracts cluster near 50%, indicating roughly even positioning relative to existing open interest levels.

JNJ Seasonality

August and early autumn have historically been active periods for pharmaceutical and healthcare names as investors position ahead of third-quarter earnings and major medical conferences in the fall season. Options activity in mid-August targeting October expirations aligns with a pattern of traders looking to capture potential catalysts in the September and October window.

JNJ Relative Performance

JNJ is trading at $256.18 today, down 0.55% on the session, but remains well above its 52-week low of $166.64 and within striking distance of its 52-week high of $274.89. The stock has recovered significant ground over the trailing year, and the current price represents a position in the upper third of its annual range, reflecting resilience relative to the broader healthcare sector's volatility over that period.